In conjunction with the detection of a recurrent, potentially pathognomonic fusion event in FLC, but not in cHCC (DNAJB1-PRKACA) [12], and in accordance with previous reports [34,35,36], all of these observations suggest that cHCC and FLC tumours do represent different entities with different biological background, manifestation, and clinical course, and thus, require distinct therapeutic handling (s. This evidence concerns the gene DNAJB1 and neoplasm.